Sunday 18 October 2026
Export SPRB’s income statement to Excel — free account
Spruce Biosciences, Inc.
SPRB Healthcare Biotechnology
Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023. In the quarter to June 2026, revenue fell 75.9%, EPS fell 90.9%, free cash flow fell 152.1% and total debt rose 427.2%, each against the same quarter a year earlier.
39.65
1.82
−4.39%
Follow SPRB
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 85,050.00 | 12,656.25 | 5,371.88 | 5,681.25 | 2,053.13 | 7.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 200,250.00 | 160,256.25 | 26,381.25 | 20,081.25 | 33,468.75 | 2,508.75 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 17 | 15 | 27 | 29 | 21 | 8 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.35 | 0.23 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 10 | 5 | — | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | — | |||||
| EBT | — | — | (10) | (13) | (30) | (42) | (46) | (48) | (53) | (39) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (474.96) | (1,079.94) | 0.00 | |||||
| Net income | — | 0 | (10) | (13) | (30) | (42) | (46) | (48) | (53) | (39) | |||||
| Depreciation | — | — | 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.70 | 8.93 | 0.00 | ||||
| Earnings | — | — | (0.44) | (1,288.04) | (370.68) | (136.09) | (147.37) | (93.23) | (96.99) | (50.83) | |||||
| Cash flow | — | — | (0.38) | (1,236.96) | (345.28) | (115.47) | (133.22) | (64.96) | (101.75) | (43.45) | |||||
| Capex | — | — | 0.00 | (0.39) | (0.93) | (0.30) | (0.03) | (0.01) | 0.00 | 0.00 | |||||
| Free cash flow | — | — | (0.38) | (1,237.35) | (346.21) | (115.77) | (133.24) | (64.98) | (101.75) | (43.45) | |||||
| Book value | — | — | 0.09 | (276.86) | 1,874.87 | 358.45 | 218.88 | 149.37 | 52.40 | 55.43 | |||||
| Shares, m | — | — | 22 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||
| P/S | — | — | — | — | — | — | — | 845.29 | 264.58 | — | |||||
| P/B | — | — | — | — | — | — | — | 111.47 | 45.08 | — | |||||
| EV/Sales | — | — | — | — | — | — | — | 836.07 | 257.05 | — | |||||
| EV/FCF | — | — | — | — | — | — | — | (253.43) | (22.55) | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (9) | (13) | (28) | (36) | (42) | (33) | (56) | (33) | ||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | — | — | |||||
| Free cash flow | — | — | (9) | (13) | (28) | (36) | (42) | (33) | (56) | (33) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 2 | 0 | 151 | 83 | 71 | 78 | 29 | 42 | ||||
| Total debt | — | — | — | 4 | 4 | 5 | 5 | 3 | 2 | — | |||||
| Net debt | — | — | (4) | 1 | (153) | (84) | (74) | (93) | (37) | (49) | |||||
| Shareholders’ equity | — | — | 2 | (3) | 149 | 111 | 68 | 77 | 29 | 43 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (412.90) | (276.50) | (35.25) | (29.23) | (43.54) | (50.55) | (71.12) | (79.34) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (95.12) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 40.70 | 54.04 | (49.73) | (32.43) | (51.35) | (66.10) | (100.70) | (109.24) | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Dec 2024
Charts ten years each
Spruce Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HUMA Humacyte, Inc. | $122.1M | — (loss-making) | — (loss-making) | +34.88% (above 0%: growing) | n/m | +17.85% (above 0%: growing) | (203.20%) | (6,649.26%) | Compare |
| OTLK Outlook Therapeutics, Inc. | $121.7M | — (loss-making) | — (loss-making) | −99.42% (below 0%: shrinking) | n/m | −76.54% (below 0%: shrinking) | (95.40%) | (124,255.17%) | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $120.8M | — (loss-making) | — | — | n/m | +43.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SPRB Spruce Biosciences, Inc. | $119.2M | — (loss-making) | — (loss-making) | −75.86% (below 0%: shrinking) | n/m | −152.10% (below 0%: shrinking) | 100.00% | 0.00% | |
| NRXP NRx Pharmaceuticals, Inc. | $117.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| HURA TuHURA Biosciences, Inc. | $116.6M | — (loss-making) | — | — | n/m | −70.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NERV Minerva Neurosciences, Inc | $115.6M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARMP Armata Pharmaceuticals, Inc. | $114.9M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| ENGN enGene Therapeutics Inc | $114.6M | — (loss-making) | — | — | n/m | +28.07% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $117.0M | — | — | +15.72% | — | −44.22% | 0.00% | (205.42%) |
Spruce Biosciences, Inc. (SPRB) key facts
- Concern: Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023.
- Spruce Biosciences, Inc. (SPRB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SPRB traded at $39.65, a market capitalization of $119.2 million.
- Return on equity was −109.2% and debt-to-equity 0.08.
- Its Altman Z-score is 36.60 (safe zone) for fiscal 2024.